Disable 2, A Versatile Tissue Matrix Multifunctional Scaffold Protein with Multifaceted Signaling: Unveiling Role in Breast Cancer for Therapeutic Revolution

Overview

Journal Cell Biochem Biophys

Specialties Biochemistry
Biophysics
Cell Biology

Date 2024 Apr 9

PMID 38594547

Authors

Nidhi N Shah

Bhavarth P Dave

Kashvi C Shah

Disha D Shah

Kunal G Maheshwari

Mehul R Chorawala

Affiliations

Soon will be listed here.

Abstract

The Disabled-2 (DAB2) protein, found in 80-90% of various tumors, including breast cancer, has been identified as a potential tumor suppressor protein. On the contrary, some hypothesis suggests that DAB2 is associated with the modulation of the Ras/MAPK pathway by endocytosing the Grb/Sos1 signaling complex, which produces oncogenes and chemoresistance to anticancer drugs, leading to increased tumor growth and metastasis. DAB2 has multiple functions in several disorders and is typically under-regulated in several cancers, making it a potential target for treatment of cancer therapy. The primary function of DAB2 is the modulation of transforming growth factor- β (TGF-β) mediated endocytosis, which is involved in several mechanisms of cancer development, including tumor suppression through promoting apoptosis and suppressing cell proliferation. In this review, we will discuss in detail the mechanisms through which DAB2 leads to breast cancer and various advancements in employing DAB2 in the treatment of breast cancer. Additionally, we outlined its role in other diseases. We propose that upregulating DAB2 could be a novel approach to the therapeutics of breast cancer.

Citing Articles

The scaffold protein disabled 2 (DAB2) and its role in tumor development and progression.

Pandya D, Parikh R, Gena R, Kothari N, Parekh P, Chorawala M Mol Biol Rep. 2024; 51(1):701.

PMID: 38822973 DOI: 10.1007/s11033-024-09653-9.

References

Howell B, Lanier L, Frank R, Gertler F, Cooper J . The disabled 1 phosphotyrosine-binding domain binds to the internalization signals of transmembrane glycoproteins and to phospholipids. Mol Cell Biol. 1999; 19(7):5179-88. PMC: 84361. DOI: 10.1128/MCB.19.7.5179. View

Liu L, Xu C, Hsieh J, Gong J, Xie D . DAB2IP in cancer. Oncotarget. 2015; 7(4):3766-76. PMC: 4826168. DOI: 10.18632/oncotarget.6501. View

Price Z, Lokman N, Yoshihara M, Kajiyama H, Oehler M, Ricciardelli C . Disabled-2 (): A Key Regulator of Anti- and Pro-Tumorigenic Pathways. Int J Mol Sci. 2023; 24(1). PMC: 9821069. DOI: 10.3390/ijms24010696. View

Ogbu S, Musich P, Zhang J, Yao Z, Howe P, Jiang Y . The role of disabled-2 (Dab2) in diseases. Gene. 2020; 769:145202. DOI: 10.1016/j.gene.2020.145202. View

Finkielstein C, Capelluto D . Disabled-2: A modular scaffold protein with multifaceted functions in signaling. Bioessays. 2016; 38 Suppl 1:S45-55. DOI: 10.1002/bies.201670907. View

Fulop V, Colitti C, Genest D, Berkowitz R, Yiu G, Ng S . DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases. Oncogene. 1998; 17(4):419-24. DOI: 10.1038/sj.onc.1201955. View

Fazili Z, Sun W, Mittelstaedt S, Cohen C, Xu X . Disabled-2 inactivation is an early step in ovarian tumorigenicity. Oncogene. 1999; 18(20):3104-13. DOI: 10.1038/sj.onc.1202649. View

Xiong Z, Yang L, Li N, Fu J, Liu P, Sun P . DAB2IP attenuates chemoresistance of triple-negative breast cancer through sequestration of RAC1 to prevent β-catenin nuclear accumulation. Clin Transl Med. 2022; 12(12):e1133. PMC: 9763535. DOI: 10.1002/ctm2.1133. View

Mok S, Wong K, Chan R, Lau C, Tsao S, Knapp R . Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. Gynecol Oncol. 1994; 52(2):247-52. DOI: 10.1006/gyno.1994.1040. View

10.

Albertsen H, Smith S, Melis R, Williams B, Holik P, Stevens J . Sequence, genomic structure, and chromosomal assignment of human DOC-2. Genomics. 1996; 33(2):207-13. DOI: 10.1006/geno.1996.0185. View

11.

Xu X, Yang W, Jackowski S, Rock C . Cloning of a novel phosphoprotein regulated by colony-stimulating factor 1 shares a domain with the Drosophila disabled gene product. J Biol Chem. 1995; 270(23):14184-91. DOI: 10.1074/jbc.270.23.14184. View

12.

Sun W, Smith E, Cohen C, Sheng Z, Xu X . Restoration of positioning control following Disabled-2 expression in ovarian and breast tumor cells. Oncogene. 2000; 19(42):4847-54. DOI: 10.1038/sj.onc.1203853. View

13.

Schwahn D, Medina D . p96, a MAPK-related protein, is consistently downregulated during mouse mammary carcinogenesis. Oncogene. 1998; 17(9):1173-8. DOI: 10.1038/sj.onc.1202038. View

14.

Trotter J, Lee G, Kazdoba T, Crowell B, Domogauer J, Mahoney H . Dab1 is required for synaptic plasticity and associative learning. J Neurosci. 2013; 33(39):15652-68. PMC: 3782631. DOI: 10.1523/JNEUROSCI.2010-13.2013. View

15.

Xu X, Yi T, Tang B, Lambeth J . Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2. Oncogene. 1998; 16(12):1561-9. DOI: 10.1038/sj.onc.1201678. View

16.

Maurer M, Cooper J . The adaptor protein Dab2 sorts LDL receptors into coated pits independently of AP-2 and ARH. J Cell Sci. 2006; 119(Pt 20):4235-46. DOI: 10.1242/jcs.03217. View

17.

Hocevar B, Smine A, Xu X, Howe P . The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway. EMBO J. 2001; 20(11):2789-801. PMC: 125498. DOI: 10.1093/emboj/20.11.2789. View

18.

Nakayama M, Nakayama A, van Lessen M, Yamamoto H, Hoffmann S, Drexler H . Spatial regulation of VEGF receptor endocytosis in angiogenesis. Nat Cell Biol. 2013; 15(3):249-60. PMC: 3901019. DOI: 10.1038/ncb2679. View

19.

Tseng C, Ely B, Pong R, Wang Z, Zhou J, Hsieh J . The role of DOC-2/DAB2 protein phosphorylation in the inhibition of AP-1 activity. An underlying mechanism of its tumor-suppressive function in prostate cancer. J Biol Chem. 1999; 274(45):31981-6. DOI: 10.1074/jbc.274.45.31981. View

20.

Figliuolo da Paz V, Ghishan F, Kiela P . Emerging Roles of Disabled Homolog 2 (DAB2) in Immune Regulation. Front Immunol. 2020; 11:580302. PMC: 7593574. DOI: 10.3389/fimmu.2020.580302. View